Inhibiting Effect of Different Administration Route of Gemcitabine Combined with Cisplatin on A549 Cell Lines / 天津医药

ABSTRACT

Objective To compare the inhibiting effect on human lung adenocarcinoma who were treated with gem?citabine combined with cisplatin chemotherapy through either arterial or intravenous route to explore the optimum adminis?tration route. Methods Human lung adenocarcinoma derived A549 cells were transplanted into 40 BALB/c-nu mice to es?tablish lung cancer model. The models were divided into 4 groupsanimals in arterial or intravenous chemotherapy groups were treated with gemcitabine 150 mg/kg combined with cisplatin 10 mg/kg through either arterial route or intravenous route. Animals in negative control group were given normal saline through caudal vein while animals in sham operation group were treated with normal saline via arterial route. Then dynamical change of tumor volume and tumor inhibiting rate were assessed , and Bcl-2 and Caspase 3 expressions were investigated using western blot. Finally inhibiting effect were compared between these two different administration routes. Results Transplanted tumors in arterial and intravenous che?motherapy groups (especially in arterial group) were suppressed, in terms of mass of tumor(g1.91±0.19, 2.61±0.21 vs 4.58± 0.46), compared to the control group (P<0.05). Furthermore, tumor inhibiting rates in arterial chemotherapy group and ve?nous chemotherapy group are 57.6%and 42.4%respectively (P<0.05). Expression of Bcl-2 was down regulated while ex?pression of Caspase-3 was up regulated upon both arterial and intravenous chemotherapy. And arterial route showed much more obvious tumor apoptosis effect than venous route. Conclusion Arterial route of gemcitabine combined with cisplatin for lung adenocarcinoma treatment is more effective to restrain the tumor growth in clinical application.